Should I buy or sell ABIVAX Société Anonyme stock right now?

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for ABIVAX Société Anonyme in the last year. There are currently 1 hold rating and 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" ABVX shares. View ABVX analyst ratings or view top-rated stocks .

What is ABIVAX Société Anonyme's stock price target for 2024?

5 brokerages have issued 1-year price targets for ABIVAX Société Anonyme's stock. Their ABVX share price targets range from $16.00 to $50.00. On average, they anticipate the company's share price to reach $32.00 in the next year. This suggests a possible upside of 124.1% from the stock's current price. View analysts price targets for ABVX or view top-rated stocks among Wall Street analysts .

How have ABVX shares performed in 2024?

ABIVAX Société Anonyme's stock was trading at $10.70 at the start of the year. Since then, ABVX shares have increased by 33.5% and is now trading at $14.28. View the best growth stocks for 2024 here .

Are investors shorting ABIVAX Société Anonyme?

ABIVAX Société Anonyme saw a decline in short interest in the month of April. As of April 15th, there was short interest totaling 113,800 shares, a decline of 29.5% from the March 31st total of 161,500 shares. Based on an average daily trading volume, of 74,700 shares, the days-to-cover ratio is currently 1.5 days. Currently, 0.2% of the shares of the stock are sold short. View ABIVAX Société Anonyme's Short Interest .

When did ABIVAX Société Anonyme IPO?

ABIVAX Société Anonyme (ABVX) raised $217 million in an IPO on Friday, October 20th 2023. The company issued 18,699,460 shares at $11.60 per share.

When did the company's lock-up period expire?

ABIVAX Société Anonyme's lock-up period expired on Wednesday, April 17th. ABIVAX Société Anonyme had issued 18,699,460 shares in its initial public offering on October 20th. The total size of the offering was $216,913,736 based on an initial share price of $11.60. Shares of the company owned by major shareholders and company insiders are now eligible to be traded as a result of the expiration of the lock-up period.

Who are ABIVAX Société Anonyme's major shareholders?

ABIVAX Société Anonyme's stock is owned by many different institutional and retail investors. Top institutional investors include Rosalind Advisors Inc. (0.60%), Capstone Investment Advisors LLC (0.10%) and BNP Paribas Financial Markets (0.01%).

How do I buy shares of ABIVAX Société Anonyme?

Shares of ABVX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:ABVX

ABIVAX Société Anonyme (ABVX) Stock Price, News & Analysis

→ This 1 Biotech Stock has been shocking the markets (From Huge Alerts) (Ad)

Free ABVX Stock Alerts

$14.28

-0.28 (-1.92%)

(As of 05/8/2024 ET)

Compare

Today's Range: $13.38
▼
$14.75
50-Day Range: $13.06
▼
$15.89
52-Week Range: $7.99
▼
$17.02

Volume: 57,401 shs
Average Volume: 97,872 shs
Market Capitalization: $898.64 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $32.00

Get ABIVAX Société Anonyme alerts:

ABIVAX Société Anonyme MarketRank™ Stock Analysis

Analyst Rating: Moderate Buy
2.80 Rating Score
Upside/Downside: 124.1% Upside
$32.00 Price Target
Short Interest: Healthy
0.19% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: N/A
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($2.98) to ($2.90) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.55 out of 5 stars

Medical Sector

442nd out of 905 stocks

Pharmaceutical Preparations Industry

201st out of 422 stocks

3.4

Analyst's Opinion

Consensus Rating
ABIVAX Société Anonyme has received a consensus rating of Moderate Buy. The company's average rating score is 2.80, and is based on 4 buy ratings, 1 hold rating, and no sell ratings.
Amount of Analyst Coverage
ABIVAX Société Anonyme has only been the subject of 3 research reports in the past 90 days.
Read more about ABIVAX Société Anonyme's stock forecast and price target.

5.0

Short Interest

Percentage of Shares Shorted
0.19% of the float of ABIVAX Société Anonyme has been sold short.
Short Interest Ratio / Days to Cover
ABIVAX Société Anonyme has a short interest ratio ("days to cover") of 1.5, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in ABIVAX Société Anonyme has recently decreased by 29.54%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
ABIVAX Société Anonyme does not currently pay a dividend.
Dividend Growth
ABIVAX Société Anonyme does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for ABVX.

N/A

News and Social Media Coverage

0.8

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, ABIVAX Société Anonyme insiders have not sold or bought any company stock.
Percentage Held by Institutions
47.91% of the stock of ABIVAX Société Anonyme is held by institutions. High institutional ownership can be a signal of strong market trust in this company.
Read more about ABIVAX Société Anonyme's insider trading history.

0.6

Earnings and Valuation

Earnings Growth
Earnings for ABIVAX Société Anonyme are expected to grow in the coming year, from ($2.98) to ($2.90) per share.

See Top Rated MarketRank™ Stocks Here

Ad Huge Alerts

This 1 Biotech Stock has been shocking the markets

Save the Date: BioStem's 2024 Q1 Call Coming Up!

About ABIVAX Société Anonyme Stock (NASDAQ:ABVX)

ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis. ABIVAX Société Anonyme was incorporated in 2013 and is headquartered in Paris, France.

ABVX Stock Price History

30 days | 90 days | 365 days | Advanced Chart

ABVX Stock News Headlines

April 30, 2024 | americanbankingnews.com

ABIVAX Société Anonyme (NASDAQ:ABVX) Receives New Coverage from Analysts at Piper Sandler

April 30, 2024 | americanbankingnews.com

ABIVAX Société Anonyme (NASDAQ:ABVX) Receives New Coverage from Analysts at Guggenheim

May 9, 2024 | Porter & Company (Ad)

Elon to Transform U.S. Economy?

A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” grift of the elites. And yet, while it threatens their wealth and power, it could be transformational for both the U.S. economy and your wealth.

April 10, 2024 | seekingalpha.com

ABIVAX Société Anonyme (AAVXF) Q4 2023 Earnings Call Transcript

April 10, 2024 | seekingalpha.com

ABVX ABIVAX Société Anonyme

April 2, 2024 | globenewswire.com

Abivax reports 2023 financial results and operational update

March 14, 2024 | morningstar.com

Abivax SA ADR ABVX

February 23, 2024 | wsj.com

Abivax S.A. ADR

May 9, 2024 | Porter & Company (Ad)

Elon to Transform U.S. Economy?

February 20, 2024 | finance.yahoo.com

ABIVAX Société Anonyme (ABVX.PA)

February 17, 2024 | morningstar.com

Abivax SA ABVX

February 13, 2024 | finance.yahoo.com

Abivax Announces Presentation of Four Abstracts for Obefazimod in Ulcerative Colitis and Sponsorship of Scientific Symposium at The 19th Congress of European Crohn’s and Colitis Organization (ECCO)